Dana Farber Cancer Institute SC (1) — Boston, Massachusetts

Dana Farber Cancer Institute SC (1) is a clinical research site located in Boston, Massachusetts, United States 02115.

Crixeo Health Trust Score: 56/100 (POOR). This profile has not yet been claimed by the site owner.

Dana Farber Cancer Institute SC (1) has participated in 2 clinical trials with 1 currently active.

Therapeutic areas: Advanced Malignancies That Harbor IDHR132 Mutations, Glioblastoma.

Sponsors: Novartis Pharmaceuticals.

Sponsor Feasibility Report

Trust Score: 56/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Dana Farber Cancer Institute SC (1)?

Dana Farber Cancer Institute SC (1) has a Crixeo Trust Score of 56/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Dana Farber Cancer Institute SC (1) conducted?

Dana Farber Cancer Institute SC (1) has 2 clinical trials on record, with 1 currently active. Their work covers Advanced Malignancies That Harbor IDHR132 Mutations, Glioblastoma.

Is Dana Farber Cancer Institute SC (1) accredited by Crixeo Health?

Dana Farber Cancer Institute SC (1) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Dana Farber Cancer Institute SC (1)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.